New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
19:05 EDTPCYCPharmacyclics publishes Phase 1b/2 study of ibrutinib in elderly patients
Pharmacyclics announced that The Lancet Oncology published results of a study evaluating ibrutinib in previously untreated elderly patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The Phase 1b/2 open-label, multicenter study evaluated 31 patients, 65 years of age and older with CLL or SLL. The primary endpoint of the study was safety, as assessed by the frequency and severity of adverse events, while the secondary objectives assessed the clinical activity of single agent ibrutinib. Only one patient out of the 31 enrolled in this cohort has had progression of disease. Across all patients, the estimated progression-free survival and overall survival at 24 months were 96.3% and 96.6%, respectively.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use